Your browser doesn't support javascript.
loading
18F-florbetapir PET as a marker of myelin integrity across the Alzheimer's disease spectrum.
Moscoso, Alexis; Silva-Rodríguez, Jesús; Aldrey, Jose Manuel; Cortés, Julia; Pías-Peleteiro, Juan Manuel; Ruibal, Álvaro; Aguiar, Pablo.
Afiliação
  • Moscoso A; Nuclear Medicine Department and Molecular Imaging Group, University Hospital Santiago de Compostela, IDIS, Travesía da Choupana S/N, 15706, Santiago de Compostela, Spain.
  • Silva-Rodríguez J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, and The Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Aldrey JM; Nuclear Medicine Department and Molecular Imaging Group, University Hospital Santiago de Compostela, IDIS, Travesía da Choupana S/N, 15706, Santiago de Compostela, Spain.
  • Cortés J; Neurology Department, University Hospital Santiago de Compostela, Travesía da Choupana S/N, 15706, Santiago de Compostela, Spain.
  • Pías-Peleteiro JM; Nuclear Medicine Department and Molecular Imaging Group, University Hospital Santiago de Compostela, IDIS, Travesía da Choupana S/N, 15706, Santiago de Compostela, Spain.
  • Ruibal Á; Neurology Department, University Hospital Santiago de Compostela, Travesía da Choupana S/N, 15706, Santiago de Compostela, Spain.
  • Aguiar P; Nuclear Medicine Department and Molecular Imaging Group, University Hospital Santiago de Compostela, IDIS, Travesía da Choupana S/N, 15706, Santiago de Compostela, Spain.
Eur J Nucl Med Mol Imaging ; 49(4): 1242-1253, 2022 03.
Article em En | MEDLINE | ID: mdl-34581847
ABSTRACT

PURPOSE:

Recent evidence suggests that PET imaging with amyloid-ß (Aß) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer's disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which demyelination, as measured with Aß PET, contributes to AD progression remains unexplored.

METHODS:

Participants with concurrent 18F-florbetapir (FBP) PET, MRI, and cerebrospinal fluid (CSF) examinations were included (241 cognitively normal, 347 Aß-positive cognitively impaired, and 207 Aß-negative cognitively impaired subjects). A subset of these participants had also available diffusion tensor imaging (DTI) images (n = 195). We investigated cross-sectional associations of FBP retention in the white matter (WM) with MRI-based markers of WM degeneration, AD clinical progression, and fluid biomarkers. In longitudinal analyses, we used linear mixed models to assess whether FBP retention in normal-appearing WM (NAWM) predicted progression of WM hyperintensity (WMH) burden and clinical decline.

RESULTS:

In AD-continuum individuals, FBP retention in NAWM was (1) higher compared with WMH regions, (2) associated with DTI-based measures of WM integrity, and (3) associated with longitudinal progression of WMH burden. FBP uptake in WM decreased across the AD continuum and with increasingly abnormal CSF biomarkers of AD. Furthermore, FBP retention in the WM was associated with large-calibre axon degeneration as reflected by abnormal plasma neurofilament light chain levels. Low FBP uptake in NAWM predicted clinical decline in preclinical and prodromal AD, independent of demographics, global cortical Aß, and WMH burden. Most of these associations were also observed in Aß-negative cognitively impaired individuals.

CONCLUSION:

These results support the hypothesis that FBP retention in the WM is myelin-related. Demyelination levels progressed across the AD continuum and were associated with clinical progression at early stages, suggesting that this pathologic process might be a relevant degenerative feature in the disease course.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Desmielinizantes / Doença de Alzheimer / Disfunção Cognitiva / Substância Branca Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Desmielinizantes / Doença de Alzheimer / Disfunção Cognitiva / Substância Branca Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha